BUSINESS

• Eisai’s Halaven Clinches NICE OK as 3rd-Line Breast Cancer Therapy
  November 7, 2016

• Mitsubishi Tanabe to Offer Compound Library to Univ. of Tokyo
  November 7, 2016

• Acne Med Epiduo Gel Hits Japan Shelves: Maruho
  November 7, 2016

• JCR to Provide Temcell for IIT in Epidermolysis Bullosa
  November 4, 2016

• Santen Profits Tumble Over 70% on Strong Yen, Divestment; Ophthalmology Biz Brisk
  November 4, 2016

• Pfizer Japan Calls Off Transfer of Innovative Drugs after Global Split Plan Scrapped
  November 4, 2016

• Mitsubishi Tanabe Licenses Cell Therapy Agent for Knee Osteoarthritis from S. Korean Firm
  November 4, 2016

• Mitsubishi Tanabe Ekes Out Sales Rise on Simponi, Other Major Products
  November 2, 2016

• Harvoni Top-Seller Drug in Japan in July-September: QuintilesIMS
  November 2, 2016

• Strong Yen Dampens Sales of 4 Japanese Majors, but Global Brands Keep Up Momentum
  November 2, 2016

• HER2-Targeting ADC Is One of Our Top Priorities: Daiichi Sankyo CEO
  November 2, 2016

• Eisai’s Midterm Strategy Focusing on Neurology, Oncology “Gradually Producing Results”: CEO Naito
  November 2, 2016

• Shionogi Shooting for New Product Sales of 200 Billion Yen in FY2020
  November 2, 2016

• Takeda Establishes Drug Discovery Company in New York in Partnership with US Research Institutions
  November 2, 2016

• Hisaharu Hirai Named as Japan Vaccine Chairman
  November 2, 2016

• Merck Serono Aims to Get Japan Nod for Avelumab in 2017: Pres. Lee
  November 2, 2016

• Takeda Mum on Kaketsuken Biz Transfer; CEO Says He Needs to Better Understand Situation
  November 1, 2016

• MSD Files Japan NDA for Bezlotoxumab for C. Difficile Infection
  November 1, 2016

• Pfizer Seeks Japan Approval of Breast Cancer Drug Palbociclib
  November 1, 2016

• Eisai’s BACE Inhibitor Enters PIII, Enrollment Begins in US
  November 1, 2016

ページ

• « 先頭
• ‹ Prev
• …
• 462
• 463
• 464
• 465
• 466
• 467
• 468
• 469
• 470
• …
• Next ›
• 最終 »